Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy [Volume 37, Issue 3, September 2018, Pages 248–256]

Eun Joo Song; Kye Hwa Jeong; Young Ae Yang; Jeong-Hoon Lim; Hee-Yeon Jung; Ji-Young Choi; Jang-Hee Cho; Chan-Duck Kim; Yong-Lim Kim; Sun-Hee Park

doi:10.23876/j.krcp.2018.37.3.248.corr

Kidney Res Clin Pract > Volume 37(4); 2018 > Article

Song, Jeong, Yang, Lim, Jung, Choi, Cho, Kim, Kim, and Park: Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy [Volume 37, Issue 3, September 2018, Pages 248–256]

Corrigendum

Kidney Research and Clinical Practice 2018;37(4):426.

Published online: December 31, 2018

DOI: https://doi.org/10.23876/j.krcp.2018.37.3.248.corr

Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy [Volume 37, Issue 3, September 2018, Pages 248–256]

Eun Joo Song¹, Kye Hwa Jeong², Young Ae Yang², Jeong-Hoon Lim², Hee-Yeon Jung², Ji-Young Choi², Jang-Hee Cho², Chan-Duck Kim², Yong-Lim Kim², Sun-Hee Park²

¹Department of Internal Medicine, Daehyun Chumdan Geriatric Hospital, Daegu, Korea

²Division of Nephrology and Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea

Correspondence: Sun-Hee Park, Division of Nephrology and Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea. E-mail: sh-park@knu.ac.kr. ORCID: https://orcid.org/0000-0002-0953-3343

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the above article (https://doi.org/10.23876/j.krcp.2018.37.3.248), there was an error in Figure 3. The authors regret this error, and the corrected figure is now presented below.

Figure 3

Kaplan-Meier analysis of anti-PLA2R antibody level and probability of renal survival (chronic kidney disease stage ≥ 3) (A), cumulative probability of complete remission (B) and spontaneous remission (C).

Anti-PLA2R ab, anti-phospholipase A2 receptor antibody.

The authors would like to apologize for any inconvenience.

TOOLS

METRICS

0 Crossref
0 Scopus
1,522 View
19 Download

Related articles

Anti-phospholipase A2 receptor antibody as a prognostic marker in patients with primary membranous nephropathy2018 ;37(3)

Anti-phospholipase A2 receptor antibodies in membranous nephropathy2018 ;37(3)

Editorial Office: #301, (Miseung Bldg.) 23, Apgujenog-ro 30-gil, Gangnam-gu, Seoul 06022, Korea
Tel: +82-2-3486-8736 Fax: +82-2-3486-8737 E-mail: registry@ksn.or.kr